ARTICLE | Company News

Sandoz responds to Amgen

November 5, 2014 2:46 AM UTC

A spokesperson for Sandoz told BioCentury the unit of Novartis AG (NYSE:NVS; SIX:NOVN) is unsurprised by a lawsuit and Citizen's Petition from Amgen Inc. (NASDAQ:AMGN) alleging the generics maker failed to properly notify Amgen after submitting a BLA for a biosimilar version of Neupogen filgrastim G-CSF.

"Neither Amgen's lawsuit nor their recent (see BioCentury, Nov. 3). ...